Co-Diagnostics, Inc. 8-K

What Happened

• Co-Diagnostics, Inc. filed an 8-K (dated March 10, 2026) reporting that Nasdaq notified the company on March 9, 2026 that it has demonstrated compliance with the $1.00 bid-price requirement and other listing criteria. As a result, Co-Diagnostics’ securities will resume trading on The Nasdaq Capital Market at the open on March 11, 2026. (Item 8.01)
• Nasdaq closed the previously disclosed listing matter before the Nasdaq Hearing Panel but imposed a Discretionary Panel Monitor through March 9, 2027. The company also disclosed preliminary, unaudited cash and cash equivalents of approximately $11.9 million as of December 31, 2025. (Item 2.02)

Key Details

• Nasdaq compliance notice dated March 9, 2026; trading to resume at market open March 11, 2026.
• Discretionary Panel Monitor in place through March 9, 2027; if closing bid < $1.00 for 30 consecutive business days during the monitor period, Nasdaq would issue a delist determination rather than grant a 180-day cure period (the company may appeal that determination).
• Preliminary, unaudited cash and cash equivalents: ~ $11.9 million as of December 31, 2025.
• Filing items: Item 8.01 (Other Events — Nasdaq matters) and Item 2.02 (Results of Operations and Financial Condition — preliminary cash disclosure).

Why It Matters

• Resumption of Nasdaq trading restores liquidity and market access for shareholders and may make it easier to buy/sell shares.
• The Panel Monitor means the company remains under heightened oversight; a sustained sub-$1 share price during the monitor period could trigger a delisting process (though the company can appeal).
• The disclosed ~$11.9M cash balance gives a snapshot of near-term liquidity, but it is preliminary and unaudited and could change when year-end financials are finalized. Investors should watch share price trends and upcoming audited financial disclosures for more definitive information.